Erowid.org: Erowid Reference 7270 : [Psychosomatic dysfunctions in the female climactericClinical effectiveness and tolerance of Kava Extract WS 1490] : Warnecke G

Erowid References Database

Warnecke G. “[Psychosomatic dysfunctions in the female climactericClinical effectiveness and tolerance of Kava Extract WS 1490]”. Fortschr Med. 1991 Feb 19;109(4):119-22. <a name="ref">Warnecke G.</a> <a href="/references/7270">"[Psychosomatic dysfunctions in the female climactericClinical effectiveness and tolerance of Kava Extract WS 1490]"</a> <i>Fortschr Med</i>. 1991 Feb 19;109(4):119-22.
Show Articles by Warnecke G Article IDs Erowid RefID: 7270 PubMedID: 2029982 Collections Hofmann Collection MDMA Collection All References	Abstract Within the framework of a randomized, placebo-controlled double-blind study, two groups each containing 20 patients with climacteric-related symptomatology were treated for a period of 8 weeks with kava WS 1490 extract 3 X 100 mg/day or a placebo preparation. The target variable - the HAMA overall score of anxiety symptomatology - revealed a significant difference in the drug-receiving group vis-à-vis the placebo group already after only 1 week of treatment. The course of such further parameters as depressive mood (DSI), subjective well-being (patient diary), severity of the disease (CGI), and the climacteric symptomatology (Kuppermann Index and Schneider scale) over the overall period of treatment demonstrate a high level of efficacy of kava extract WS 1490 in neurovegetative and psychosomatic dysfunctions in the climacteric, associated with very good tolerance of the preparation.
Comments and Responses to this Article #
Submit Comment

[ Cite HTML ]